Chromatin Bioscience is pleased to announce an ongoing research collaboration with Purespring Therapeutics, a precision nephrology company leading the development of targeted, first-in-class genetic ...

To solve this critical challenge, he founded Nephrogen in 2022, a biotech startup that uses AI and advanced screening to ...

Purespring Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference London – 14 October 2025 - Purespring ...

“Beyond UniQure, the pipeline includes highly promising approaches that will ideally move the goal from merely managing ...

A uniQure gene therapy slowed progression of Huntington’s disease by 75% after three years, statistically significant clinical trial results the company says will support plans for a regulatory ...

Gene therapy is becoming a powerful way to treat challenging diseases that don’t respond to traditional treatments, and researchers now report the first success in modifying genes to slow Huntington’s ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Scientists report the first therapy to slow the deadly brain disease. A one-time gene therapy treatment has shown remarkable success in slowing the progression of Huntington's disease in a preliminary ...

An experimental gene therapy developed by researchers at UCLA, University College London and Great Ormond Street Hospital has ...

Preliminary results from a small trial offer the clearest evidence yet that the brain disease’s progression can be slowed. A one-time gene therapy can markedly slow the progression of Huntington’s ...

Chromatin Bioscience is pleased to announce an ongoing research collaboration with Purespring Therapeutics, a precision nephrology company ...